Ajax Therapeutics
Targeted small molecule therapeutics for hematologic cancers with improved selectivity profiles
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2019
- Latest Form D
- $95M, May 2024
- Total capital
- $140M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $140M
- 3 Form D · last May 2024
- 29 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 35 pending · first 2023
- Rank in peer group#7 of 55
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$95M
- Private capital raisedForm D · SEC · 2nd filing$37.4M
- Private capital raisedForm D · SEC · 1st filing$8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 55 peers
Line = medianBiotech · Software
- Granted patents#7 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- David SchnellDirectorNamed in SEC Form D filings
- Martin VogelbaumExecutive Officer, DirectorNamed in SEC Form D filings
- Ramy FaridDirectorNamed in SEC Form D filings
- Ross LevineDirectorNamed in SEC Form D filings
- Scott PlatshonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 40- PendingPyrrolo-pyridazine Inhibitors Of JAK2USPTOApplication 19320373
- Granted6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsUSPTOUS 12,275,717
- GrantedForms And Compositions Of Inhibitors Of JAK2USPTOUS 12,162,881
Show all 40 patent records
- Pyrrolo-pyridazine Inhibitors Of JAK2Mar 19, 2026 · Application 19320373Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApr 15, 2025 · US 12,275,717Granted
- Forms And Compositions Of Inhibitors Of JAK2Dec 10, 2024 · US 12,162,881Granted
- Forms And Compositions Of A JAK2 InhibitorNov 7, 2024 · Application 18653857Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsAug 1, 2024 · Application 18617294Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsJul 23, 2024 · US 12,043,632Granted
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApr 30, 2024 · US 11,970,494Granted
- Heterocyclic Amide And Urea Compounds As JAK2 InhibitorsApr 11, 2024 · Application 18366187Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsJul 4, 2023 · US 11,691,963Granted
- JAK2 Inhibitor CompoundsApplication PCTUS2023072255Pending
- Heterocyclic Amide And Urea Compounds As JAK2 InhibitorsApplication PCTUS2023029603Pending
- Forms And Compositions Of A JAK2 InhibitorApplication 63499765Pending
- Azaindazoles As JAK2 InhibitorsApplication 63478833Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication PCTUS2022049220Pending
- Forms And Compositions Of Inhibitors Of JAK2Application PCTUS2022049223Pending
- JAK2 Inhibitor CompoundsApplication 63373156Pending
- Heterocyclic Amide And Urea Compounds As JAK2 InhibitorsApplication 63395992Pending
- Heteroaryloxy Triazolo- And Imidazo-azines As JAK2 InhibitorsApplication PCTUS2022038654Pending
- Pyrazolo Piperazines As JAK2 InhibitorsApplication PCTUS2022038657Pending
- Heteroaryloxy Thiazolo Azines As JAK2 InhibitorsApplication PCTUS2022038661Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication 63354403Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication PCTUS2021064830Pending
- Forms And Compositions Of Inhibitors Of JAK2Application 63277419Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication 63277343Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication 63277337Pending
- Heteroaryloxy Thiazolo Azines As JAK2 InhbitorsApplication 63226888Pending
- Heteroaryloxy Triazolo- And Imidazo-azines As JAK2 InhibitorsApplication 63226889Pending
- Pyrazolo Piperazines As JAK2 InhibitorsApplication 63226892Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication 63218097Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication PCTUS2021030926Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication 63130254Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication 63130251Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication 63087717Pending
- Pyrrolo-pyridazine Inhibitors Of JAK2Application PCTUS2025044991Pending
- 6-HETEROARYLOXY Benzimidazoles And Azabenzimidazoles As JAK2 InhibitorsApplication 63020645Pending
- Pyrrolo-pyridazine Inhibitors Of JAK2Application 63831517Pending
- Macrocyclic Heteroaromatic Inhibitors Of JAK2Application PCTUS2025030295Pending
- 5,6 Bicyclic Heteroaromatic Inhibitors Of JAK2Application PCTUS2025026634Pending
- Macrocyclic Heteroaromatic Inhibitors Of JAK2Application 63736937Pending
- Macrocyclic Heteroaromatic Inhibitors Of JAK2Application 63650506Pending
Related companies, and why
- Xilio TherapeuticsSimilar federal contract value in Biotech · null in contracts
- EvozyneSimilar federal contract value in Biotech · null in contracts
- ASTROCYTE PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- Imbria PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- AMIDEBIO, LLCSimilar federal contract value in Biotech · null in contracts
- CRIMSON BIOPHARM INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .